Literature DB >> 23197289

Importance of fiberoptic bronchoscopy in identifying asthma phenotypes to direct personalized therapy.

Steven E Lommatzsch1, Richard J Martin, James T Good.   

Abstract

PURPOSE OF REVIEW: This review summarizes the phenotyping of refractory asthma with an emphasis on how direct bronchoscopic observation and analysis of bronchoalveolar lavage (BAL), biopsy, and brushings of the airways helps direct specific personalized therapy. Additional testing used in phenotyping asthmatic patients is reviewed. RECENT
FINDINGS: Several studies and publications over the past decade have emphasized the importance of phenotyping refractory asthmatic patients to offer a better understanding of the pathobiology of disease. Bronchoscopy is a useful tool in phenotyping asthma with objective data obtained from BAL, endobronchial biopsy, and brushings. Phenotyping asthma with bronchoscopy affords personalized and successful therapy.
SUMMARY: By using fiberoptic bronchoscopy, specific asthma phenotypes can be identified: laryngopharyngeal reflux with silent aspiration; subacute bacterial infection; tissue eosinophilia; a combination of two or three of these; and nonspecific. Identifying these phenotypes and personalizing therapy with bronchoscopy leads to improved outcomes.

Entities:  

Mesh:

Year:  2013        PMID: 23197289     DOI: 10.1097/MCP.0b013e32835a5bdc

Source DB:  PubMed          Journal:  Curr Opin Pulm Med        ISSN: 1070-5287            Impact factor:   3.155


  5 in total

Review 1.  Mepolizumab for severe refractory eosinophilic asthma: evidence to date and clinical potential.

Authors:  Francesco Menzella; Mirco Lusuardi; Carla Galeone; Sofia Taddei; Nicola Facciolongo; Luigi Zucchi
Journal:  Ther Adv Chronic Dis       Date:  2016-08-11       Impact factor: 5.091

Review 2.  Clinical usefulness of mepolizumab in severe eosinophilic asthma.

Authors:  Francesco Menzella; Mirco Lusuardi; Gloria Montanari; Carla Galeone; Nicola Facciolongo; Luigi Zucchi
Journal:  Ther Clin Risk Manag       Date:  2016-06-08       Impact factor: 2.423

Review 3.  Innovative treatments for severe refractory asthma: how to choose the right option for the right patient?

Authors:  Francesco Menzella; Carla Galeone; Francesca Bertolini; Claudia Castagnetti; Nicola Facciolongo
Journal:  J Asthma Allergy       Date:  2017-08-30

4.  Benefits and risks of bronchoalveolar lavage in severe asthma in children.

Authors:  Raja Ben Tkhayat; Jessica Taytard; Harriet Corvol; Laura Berdah; Blandine Prévost; Jocelyne Just; Nadia Nathan
Journal:  ERJ Open Res       Date:  2021-12-06

Review 5.  The clinical profile of benralizumab in the management of severe eosinophilic asthma.

Authors:  Francesco Menzella; Mirco Lusuardi; Carla Galeone; Nicola Facciolongo; Luigi Zucchi
Journal:  Ther Adv Respir Dis       Date:  2016-09-09       Impact factor: 4.031

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.